Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria

Diabetic Medicine

Volumn 20, Issue 1, 2003, Pages 16-22

  Leurs, Paul B ^a,b   Van Oerle, R ^a   Hamulyak, K ^a   Wolffenbuttel, B H R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Oosterschelde Hospital   (Netherlands)

Author keywords

Atherosclerosis; Endothelial dysfunction; Haemostatic parameters; Microvascular complications; Tissue factor pathway inhibitor

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PARAMETER; PROTEIN SECRETION; PROTEINURIA; RETINOPATHY;

ADULT; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; FEMALE; HEPARIN; HUMANS; LIPOPROTEINS; MALE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0037236324     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00786.x     Document Type: Article

References (42)

1. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early nephropathy. Lancet 1989; i: 461-463.
2. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H et al. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-988.
3. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GDO et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41: 909-913.
4. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinol 1992; 3: 439-449.
5. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
6. Valentin S, Larnkjoer A, Ostergaard P, Ilum Nielsen J, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183.
7. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor in patients with IDDM. Diabetes 1995; 44: 80-84.
8. Leurs PB, van Oerle R, Wolffenbuttel BHR, Hamulyak K. D-glucose increases tissue factor pathway inhibitor (TFPI) release from cultured endothelial cells after heparin stimulation. Thromb Haemostas 1995; 73: 1383 (Abstr.).
9. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-1120.
10. Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996; 19: 441-445.
11. Leurs PB, van Oerle R, Wolffenbuttel BHR, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemostas 1997; 77: 472-476.
12. Huvers FC, Leeuw PW, Houben AJHM, de Haan CHA, Hamulyak K, Schouten H et al. Endothelial-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300-1307.
13. Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989; 72: 391-396.
14. Moor E, Hamsten A, Karpe F, Båvenholm P, Blombäck M, Silveira A. Relationship of tissue pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemostas 1994; 71: 707-712.
15. Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemostas 1994; 71: 275-279.
16. Rigla M, Mateo J, Fontcubera J, de Souto JC, Leiva A, Pérez A. Normalisation of tissue factor pathway inhibitor activity after glycemic control optimisation in type 1 diabetic patients. Thromb Haemostas 2000; 84: 223-227.
17. Ellis D, Coonrod BA, Dorman JS, Kelsey SF, Becker DJ, Avner ED et al. Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. Am J Kidney Dis 1989; 13: 321-328.
18. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
19. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
20. Stehouwer CDA, Zellenrath P, Polak BCP, Baarsma GS, Nauta JJP, Donker AJM et al. Von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia 1992; 35: 555-559.
21. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW. Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem 1983; 258: 11672-11677.
22. Wu VY, Wilson B, Cohen MP. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 1987; 36: 679-683.
23. Kofoed-Enevoldsen A, Noonan D, Deckert T. Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: effect of short-term blood glucose control in diabetic rats. Diabetologia 1993; 36: 310-315.
24. Deckert T, Horowitz IM, Kofoed-Enevolden A, Kjellen L, Deckert M, Lykkelund C et al. Possible genetic defects in regulation of glycosaminoglycans in patients with diabetic nephropathy. Diabetes 1991; 40: 764-770.
25. Groggel GC, Stevenson J, Hovingh P, Linker A, Border WA. Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int 1988; 33: 517-523.
26. Cotran RS, Rennke HG. Anionic sites and the mechanisms of proteinuria. N Engl J Med 1983; 309: 1050-1052.
27. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Diabetes 1987; 36: 374-381.
28. Raz I, Havivi Y, Yarom R. Reduced negative surface charge on arterial endothelium of diabetic rats. Diabetologia 1988; 31: 618-620.
29. Kjellén L, Bielefeld D, Höök M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983; 32: 337-342.
30. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986; 29: 282-286.
31. Shimano H, Takahashi K, Kawakami M, Gotoda T, Harada K, Shimada M et al. Elevated serum and urinary thrombomodulin levels in patients with non-insulin-dependent diabetes mellitus. Clin Chim Acta 1994; 225: 89-96.
32. Lamberton RP, Goodman AD, Kassoff A, Rubin CL, Treble DH, Saba TM et al. Von Willebrand factor (VIIIR. Ag), fibronectin, and insulin-like growth factors I and II in diabetic retinopathy and nephropathy. Diabetes 1984; 33: 125-129.
33. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
34. Gonzalez J, Colwell A, Sarji KE, Nair RMG, Sagel J. Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIII R. vWF) in diabetes mellitus. Thromb Res 1980; 17: 261-266.
35. Juhan-Vague I, Vague P, Poisson C, Aillaud MF, Mendez C, Collen D. Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetes. Thromb Haemostas 1984; 51: 97-98.
36. Bahru Y, Kesteven P, Alberti KG, Walker M. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabet Med 1993; 10: 802-806.
37. Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism. Am J Hypertens 1991; 4: 168S-171S.
38. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-278.
39. Blann AD, Naqvi T, Waite M, McCollum CN. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-111.
40. Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, den Ottolander GJH. Von Willebrand factor and the development of diabetic nephropathy in insulin-dependent diabetes mellitus. Diabetes 1991; 40: 971-976.
41. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837.
42. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp (a). Atheroscl Thromb 1993; 13: 1066-1075.